In Parkinson's disease, prior exenatide exposure gave a 5.6-point motor score advantage versus controls after treatment cessation.
In plain wordsPatients with Parkinson's disease previously receiving exenatide had better motor scores than controls after treatment stopped.
- Peptide
- Exenatide (exendin-4)
- Outcome
- DecreaseMDS-UPDRS part 3 motor score
- Study
n = 44
- Comparator
- Randomized controls
- Outcome group
- Exercise and physical function · Nervous system and cognition
- Studied dose
- 10ug bd · twelve monthsAs given in this study (human).
Measurements
- MDS-UPDRS part 3 difference vs controls
- 5.6 points
- exenatide-exposed vs randomized controls, 12 months after cessation
Source sentences
Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2-9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale.
3 context sentences(design, population, supporting numbers)
All participants from an open label, randomised controlled trial of exenatide as a treatment for Parkinson's disease, were invited for a further follow up assessment at the UCL Institute of Neurology.
This visit included all 20 individuals who had previously completed twelve months exposure to exenatide 10ug bd and the 24 individuals who had acted as randomised controls.
This assessment was thus 24 months after their original baseline visit, i.e. 12 months after cessation of exenatide.